CSL FY profit up, mulls buyback

By Maggie Lu Yueyang

Revenue in the period increased 7. 7 per cent to $US5. 33bn. "We continue to see robust global demand for plasma therapies," CSL chief executive Paul Perreault said.

CSL, which generates 90 per cent of its revenue outside Australia, said it expected net profit in the current financial year to rise about 12 per cent in constant currency terms.

Blood products maker CSL posted a 7. 8 per cent jump in full-year profit as sales of immunoglobulin products surged 12 per cent amid robust market conditions.

Alan has been a trusted source of investment advice to Australians for many years, and in 2005 he founded Eureka Report - Australia’s #1 online investment report.

Along with Robert Gottliebsen and Stephen Bartholomeusz, Alan also founded Business Spectator, the popular business news and commentary website.

Read more here: Business Spectator

    

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>